Diana V. Do, MD: Therapeutic Benefit of Aflibercept 8 mg for DME in PHOTON Trial

At ARVO 2023, Do discusses the benefit of aflibercept 8 mg for DME in the phase 2/3 PHOTON trial, demonstrating non-inferiority in BCVA vs aflibercept 2 mg and no new safety concerns.

Related Keywords

New Orleans ,Louisiana ,United States , ,Byers Eye Institute ,Association For Research ,Stanford University Dianav Do ,Stanford University School ,Stanford University ,Ophthalmology Annual Meeting ,During Weeks ,Diabetic Retinopathy Severity Score ,